Megan Hollasch

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication OncologyLive, aiding in all aspects of the publication process, as well as content for OncLive.com.

Articles

A Decrease in Innovation Is a Large Concern With New IRA Policies in Oncology

September 4th 2024

Jeff Patton, MD, details considerations with the Medicare Drug Price Negotiation Program Draft Guidance and its effects in the community setting.

Vice President of COA Unpacks Effects of the Medicare Drug Price Negotiation Program in the Community

September 3rd 2024

Debra Patt, MD, PhD, MBA, FASCO, details how the Medicare Drug Price Negotiation Program Draft Guidance will affect community oncologists and practices.

Dual Checkpoint Blockade Usurps PD-1 Monotherapy as Gold Standard in Unresectable Melanoma

August 28th 2024

Ankit Mangla, MD, expands on key survival data from the phase 2/3 RELATIVITY-047 trial in previously untreated, unresectable, or metastatic melanoma.

Nailing it Down: What Will AI’s Role Be in Cancer Care?

August 28th 2024

Krishnansu S. Tewari, MD, details the current and possible future applications of AI in cancer care as well as the limitations of the technology.

PARP Inhibitors and ADCs Spark Change Across Ovarian and Cervical Cancer Paradigms

August 26th 2024

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.

Dostarlimab Plus Chemotherapy Opens Doors Across Endometrial Cancer Subtypes

August 23rd 2024

Krishnansu S. Tewari, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

The HR-Positive Breast Cancer Treatment Paradigm Sits on the Cusp of Significant Shifts

August 22nd 2024

Shipra Gandhi, MD, highlights findings with oral SERDs in HR-positive breast cancer and options to consider after progression on CDK4/6 inhibitors.

ODAC Vote Aims to Introduce Clarity on Phase of Treatment Benefits in Resectable NSCLC

August 22nd 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail new trial design proposals for perioperative regimens in resectable NSCLC.

A New Wave of Endocrine Therapies Are Emerging in HR+ Breast Cancer

August 21st 2024

Jason A. Mouabbi, MD, discusses novel endocrine and targeted therapies that may overcome CDK4/6 resistance in HR-positive, HER2-negative breast cancer.

Future Perioperative Trial Designs in NSCLC Need Adjustments Per FDA ODAC Consensus

August 20th 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, discuss data with perioperative durvalumab in resectable NSCLC in light of the ODAC decision.

Sacituzumab Govitecan Displays Activity in Advanced/Metastatic Endometrial Cancer

August 19th 2024

Treatment with sacituzumab govitecan led to antitumor activity in endometrial cancer and TROP-2 expression did not appear to affect response to the agent.

Adagrasib/Cetuximab Combo Marks the Beginning of the RAS-Targeting Era in CRC

August 19th 2024

Rona Yaeger, MD, details the FDA approval of adagrasib plus cetuximab in KRAS G12C-mutated colorectal cancer and how the approval will advance the field.

The Noninvasive Biomarker KIM-1 Is Front and Center in RCC Investigations

August 15th 2024

Brian Rini, MD, and Robert Uzzo, MD, MBA, FACS, highlight the utility of the potential biomarker KIM-1 in renal cell carcinoma.

Pirtobrutinib Displays Efficacy in Patients With Richter Transformation

August 15th 2024

Pirtobrutinib was safe and demonstrated activity in patients with Richter transformation, according to a subgroup analysis of the BRUIN trial.

Analyzing the “RAS Pie” for Methods to Target Mutations in GI Cancers

August 14th 2024

The acceleration of targeted therapy drug development has led investigators to home in on RAS mutations as agents are approved in colorectal cancer.

Cannabis-Use Disorder Demonstrates a Link With Developing Head and Neck Cancer

August 14th 2024

Cannabis-related disorder was associated with the development of head and neck cancer in adults.

Wearable-Captured Metrics and ePROs Prove Feasible as Digital Ecosystem in Waldenström Macroglobulinemia

August 12th 2024

Wearable-captured physiological metrics and electronic patient reported outcomes were practical and generated knowledge in Waldenström macroglobulinemia.

Atezolizumab/Bevacizumab Represents Potential Therapeutic Option in Child-Pugh B7 HCC

August 12th 2024

Atezolizumab plus bevacizumab showed efficacy in patients with hepatocellular carcinoma who had Child-Pugh B7 liver function.

Dealing With Progression in HR+/HER2– mBC: Could a CDK4/6 Inhibitor Swap be the Solution?

August 11th 2024

Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Research Across 5 Sarcoma Stem Cell Subtypes Identifies EZH2 as a Potential Therapeutic Target

August 9th 2024

R. Lor Randall, MD, FACS, details findings from a genetic and epigenetic study showing 5 sarcoma subtypes had EZH2 activity and a shared epigenetic profile.